Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Virology Journal
Published in: Virology Journal 1/2007

Open Access 01-12-2007 | Research

Regulation of HTLV-1 Gag budding by Vps4A, Vps4B, and AIP1/Alix

Authors: Shuzo Urata, Hideyoshi Yokosawa, Jiro Yasuda

Published in: Virology Journal | Issue 1/2007

Login to get access

Abstract

Background

HTLV-1 Gag protein is a matrix protein that contains the PTAP and PPPY sequences as L-domain motifs and which can be released from mammalian cells in the form of virus-like particles (VLPs). The cellular factors Tsg101 and Nedd4.1 interact with PTAP and PPPY, respectively, within the HTLV-1 Gag polyprotein. Tsg101 forms a complex with Vps28 and Vps37 (ESCRT-I complex) and plays an important role in the class E Vps pathway, which mediates protein sorting and invagination of vesicles into multivesicular bodies. Nedd4.1 is an E3 ubiquitin ligase that binds to the PPPY motif through its WW motif, but its function is still unknown. In the present study, to investigate the mechanism of HTLV-1 budding in detail, we analyzed HTLV-1 budding using dominant negative (DN) forms of the class E proteins.

Results

Here, we report that DN forms of Vps4A, Vps4B, and AIP1 inhibit HTLV-1 budding.

Conclusion

These findings suggest that HTLV-1 budding utilizes the MVB pathway and that these class E proteins may be targets for prevention of mother-to-infant vertical transmission of the virus.
Appendix
Available only for authorised users
Literature
1.
Dorweiler IJ, Ruone SJ, Wang H, Burry RW, Mansky LM: Role of the human T-cell leukemia virus type 1 PTAP motif in Gag targeting and particle release. J Virol 2006, 80: 3634-3643. 10.1128/JVI.80.7.3634-3643.2006PubMedPubMedCentralCrossRef
2.
Heidecker G, Lloyd PA, Fox K, Nagashima K, Derse D: Late assembly motifs of human T-cell leukemia virus type 1 and their relative roles in particle release. J Virol 2004, 78: 6636-6648. 10.1128/JVI.78.12.6636-6648.2004PubMedPubMedCentralCrossRef
3.
Blot V, Perugi F, Gay B, Prevost MC, Briant L, Tangy F, Abriel H, Staub O, Dokhelar MC, Pique C: Nedd4.1-mediated ubiquitination and subsequent recruitment of Tsg101 ensure HTLV-1 Gag trafficking towards the multivesicular body pathway prior to virus budding. J Cell Sci 2004, 117: 2357-2367. 10.1242/jcs.01095PubMedCrossRef
4.
Sakurai A, Yasuda J, Takano H, Tanaka Y, Hatakeyama M, Shida H: Regulation of human T-cell leukemia virus type 1 (HTLV-1) budding by ubiquitin ligase Nedd4. Microbes Infect 2004, 6: 150-156. 10.1016/j.micinf.2003.10.011PubMedCrossRef
5.
Wang H, Machesky NJ, Mansky LM: Both the PPPY and PTAP motifs are involved in human T-cell leukemia virus type 1 particle release. J Virol 2004, 78: 1503-1512. 10.1128/JVI.78.3.1503-1512.2004PubMedPubMedCentralCrossRef
6.
Bouamr F, Melillo JA, Wang MQ, Nagashima K, de Los Santos M, Rein A, Goff SP: PPPYVEPTAP motif is the late domain of human T-cell leukemia virus type 1 Gag and mediates its functional interaction with cellular proteins Nedd4 and Tsg101 [corrected]. J Virol 2003, 77: 11882-11895. 10.1128/JVI.77.22.11882-11895.2003PubMedPubMedCentralCrossRef
7.
Le Blanc I, Prevost MC, Dokhelar MC, Rosenberg AR: The PPPY motif of human T-cell leukemia virus type 1 Gag protein is required early in the budding process. J Virol 2002, 76: 10024-10029. 10.1128/JVI.76.19.10024-10029.2002PubMedPubMedCentralCrossRef
8.
Yasuda J, Hunter E: A proline-rich motif (PPPY) in the Gag polyprotein of Mason-Pfizer monkey virus plays a maturation-independent role in virion release. J Virol 1998, 72: 4095-4103.PubMedPubMedCentral
9.
Shehu-Xhilaga M, Ablan S, Demirov DG, Chen C, Montelaro RC, Freed EO: Late domain-dependent inhibition of equine infectious anemia virus budding. J Virol 2004, 78: 724-732. 10.1128/JVI.78.2.724-732.2004PubMedPubMedCentralCrossRef
10.
Licata JM, Simpson-Holley M, Wright NT, Han Z, Paragas J, Harty RN: Overlapping motifs (PTAP and PPEY) within the Ebola virus VP40 protein function independently as late budding domains: involvement of host proteins TSG101 and VPS-4. J Virol 2003, 77: 1812-1819. 10.1128/JVI.77.3.1812-1819.2003PubMedPubMedCentralCrossRef
11.
Patton GS, Morris SA, Chung W, Bieniasz PD, McClure MO: Identification of domains in gag important for prototypic foamy virus egress. J Virol 2005, 79: 6392-6399. 10.1128/JVI.79.10.6392-6399.2005PubMedPubMedCentralCrossRef
12.
Urata S, Noda T, Kawaoka Y, Yokosawa H, Yasuda J: Cellular factors required for Lassa virus budding. J Virol 2006, 80: 4191-4195. 10.1128/JVI.80.8.4191-4195.2006PubMedPubMedCentralCrossRef
13.
Urata S, Noda T, Kawaoka Y, Morikawa S, Yokosawa H, Yasuda J: Interaction of Tsg101 with Marburg virus VP40 depends on the PPPY motif, but not the PT/SAP motif as in the case of Ebola virus, and Tsg101 plays a critical role in the budding of Marburg virus-like particles induced by VP40, NP, and GP. J Virol 2007, 81: 4895-4899. 10.1128/JVI.02829-06PubMedPubMedCentralCrossRef
14.
Xiang Y, Cameron CE, Wills JW, Leis J: Fine mapping and characterization of the Rous sarcoma virus Pr76gag late assembly domain. J Virol 1996, 70: 5695-5700.PubMedPubMedCentral
15.
Wills JW, Cameron CE, Wilson CB, Xiang Y, Bennett RP, Leis J: An assembly domain of the Rous sarcoma virus Gag protein required late in budding. J Virol 1994, 68: 6605-6618.PubMedPubMedCentral
16.
Noda T, Sagara H, Suzuki E, Takada A, Kida H, Kawaoka Y: Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J Virol 2002, 76: 4855-4865. 10.1128/JVI.76.10.4855-4865.2002PubMedPubMedCentralCrossRef
17.
Jasenosky LD, Neumann G, Lukashevich I, Kawaoka Y: Ebola virus VP40-induced particle formation and association with the lipid bilayer. J Virol 2001, 75: 5205-5214. 10.1128/JVI.75.11.5205-5214.2001PubMedPubMedCentralCrossRef
18.
Perez M, Craven RC, de la Torre JC: The small RING finger protein Z drives arenavirus budding: implications for antiviral strategies. Proc Natl Acad Sci USA 2003, 100: 12978-12983. 10.1073/pnas.2133782100PubMedPubMedCentralCrossRef
19.
Strecker T, Eichler R, Meulen J, Weissenhorn W, Dieter Klenk H, Garten W, Lenz O: Lassa virus Z protein is a matrix protein and sufficient for the release of virus-like particles [corrected]. J Virol 2003, 77: 10700-10705. 10.1128/JVI.77.19.10700-10705.2003PubMedPubMedCentralCrossRef
20.
Eichler R, Strecker T, Kolesnikova L, ter Meulen J, Weissenhorn W, Becker S, Klenk HD, Garten W, Lenz O: Characterization of the Lassa virus matrix protein Z: electron microscopic study of virus-like particles and interaction with the nucleoprotein (NP). Virus Res 2004, 100: 249-255. 10.1016/j.virusres.2003.11.017PubMedCrossRef
21.
Yuan B, Li X, Goff SP: Mutations altering the moloney murine leukemia virus p12 Gag protein affect virion production and early events of the virus life cycle. Embo J 1999, 18: 4700-4710. 10.1093/emboj/18.17.4700PubMedPubMedCentralCrossRef
22.
Garrus JE, von Schwedler UK, Pornillos OW, Morham SG, Zavitz KH, Wang HE, Wettstein DA, Stray KM, Cote M, Rich RL, et al.: Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell 2001, 107: 55-65. 10.1016/S0092-8674(01)00506-2PubMedCrossRef
23.
von Schwedler UK, Stuchell M, Muller B, Ward DM, Chung HY, Morita E, Wang HE, Davis T, He GP, Cimbora DM, et al.: The protein network of HIV budding. Cell 2003, 114: 701-713. 10.1016/S0092-8674(03)00714-1PubMedCrossRef
24.
Martin-Serrano J, Eastman SW, Chung W, Bieniasz PD: HECT ubiquitin ligases link viral and cellular PPXY motifs to the vacuolar protein-sorting pathway. J Cell Biol 2005, 168: 89-101. 10.1083/jcb.200408155PubMedPubMedCentralCrossRef
25.
Yasuda J, Nakao M, Kawaoka Y, Shida H: Nedd4 regulates egress of Ebola virus-like particles from host cells. J Virol 2003, 77: 9987-9992. 10.1128/JVI.77.18.9987-9992.2003PubMedPubMedCentralCrossRef
26.
Yasuda J, Hunter E, Nakao M, Shida H: Functional involvement of a novel Nedd4-like ubiquitin ligase on retrovirus budding. EMBO Rep 2002, 3: 636-640. 10.1093/embo-reports/kvf132PubMedPubMedCentralCrossRef
27.
Fisher RD, Chung HY, Zhai Q, Robinson H, Sundquist WI, Hill CP: Structural and biochemical studies of ALIX/AIP1 and its role in retrovirus budding. Cell 2007, 128: 841-852. 10.1016/j.cell.2007.01.035PubMedCrossRef
28.
Chen C, Vincent O, Jin J, Weisz OA, Montelaro RC: Functions of early (AP-2) and late (AIP1/ALIX) endocytic proteins in equine infectious anemia virus budding. J Biol Chem 2005, 280: 40474-40480. 10.1074/jbc.M509317200PubMedCrossRef
29.
Munshi UM, Kim J, Nagashima K, Hurley JH, Freed EO: An Alix fragment potently inhibits HIV-1 budding: characterization of binding to retroviral YPXL late domains. J Biol Chem 2007, 282: 3847-3855. 10.1074/jbc.M607489200PubMedCrossRef
30.
Irie T, Shimazu Y, Yoshida T, Sakaguchi T: The YLDL sequence within Sendai virus M protein is critical for budding of virus-like particles and interacts with Alix/AIP1 independently of C protein. J Virol 2007, 81: 2263-2273. 10.1128/JVI.02218-06PubMedPubMedCentralCrossRef
31.
Gottwein E, Bodem J, Muller B, Schmechel A, Zentgraf H, Krausslich HG: The Mason-Pfizer monkey virus PPPY and PSAP motifs both contribute to virus release. J Virol 2003, 77: 9474-9485. 10.1128/JVI.77.17.9474-9485.2003PubMedPubMedCentralCrossRef
32.
Kian Chua P, Lin MH, Shih C: Potent inhibition of human Hepatitis B virus replication by a host factor Vps4. Virology 2006, 354: 1-6. 10.1016/j.virol.2006.07.018PubMedCrossRef
33.
Strack B, Calistri A, Craig S, Popova E, Gottlinger HG: AIP1/ALIX is a binding partner for HIV-1 p6 and EIAV p9 functioning in virus budding. Cell 2003, 114: 689-699. 10.1016/S0092-8674(03)00653-6PubMedCrossRef
34.
Schmitt AP, Leser GP, Morita E, Sundquist WI, Lamb RA: Evidence for a new viral late-domain core sequence, FPIV, necessary for budding of a paramyxovirus. J Virol 2005, 79: 2988-2997. 10.1128/JVI.79.5.2988-2997.2005PubMedPubMedCentralCrossRef
35.
Irie T, Licata JM, McGettigan JP, Schnell MJ, Harty RN: Budding of PPxY-containing rhabdoviruses is not dependent on host proteins TGS101 and VPS4A. J Virol 2004, 78: 2657-2665. 10.1128/JVI.78.6.2657-2665.2004PubMedPubMedCentralCrossRef
36.
Goila-Gaur R, Demirov DG, Orenstein JM, Ono A, Freed EO: Defects in human immunodeficiency virus budding and endosomal sorting induced by TSG101 overexpression. J Virol 2003, 77: 6507-6519. 10.1128/JVI.77.11.6507-6519.2003PubMedPubMedCentralCrossRef
Metadata
Title
Regulation of HTLV-1 Gag budding by Vps4A, Vps4B, and AIP1/Alix
Authors
Shuzo Urata
Hideyoshi Yokosawa
Jiro Yasuda
Publication date
01-12-2007
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2007
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-4-66

Other articles of this Issue 1/2007

Virology Journal 1/2007 Go to the issue

Debate

Applying the scientific method when assessing the influence of migratory birds on the dispersal of H5N1

Research

Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Δ30 with those of DEN1

Research

Antisense RNA directed to the human papillomavirus type 16 E7 mRNA from herpes simplex virus type 1 derived vectors is expressed in CaSki cells and downregulates E7 mRNA

Review

Epidemics to eradication: the modern history of poliomyelitis

Research

Imperfect DNA mirror repeats in the gag gene of HIV-1 (HXB2) identify key functional domains and coincide with protein structural elements in each of the mature proteins

Methodology

Recombination-ready Sindbis replicon expression vectors for transgene expression
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits